Radiography
Volume 18, Issue 1 , Pages 15-20 , February 2012

Interventional oncology

  • Tze Wah

      Affiliations

    • Leeds Teaching Hospitals, NHS Trust, UK
    • ,
  • David Breen

      Affiliations

    • Southampton General Hospital, UK
    • ,
  • Jai Patel

      Affiliations

    • Leeds Teaching Hospitals, NHS Trust, UK
    • ,
  • Tony Nicholson

      Affiliations

    • Leeds Teaching Hospitals, NHS Trust, UK
    • Corresponding Author InformationCorresponding author. Radiology Department, Leeds General Infirmary, Leeds LS13EX, UK. Tel.: +44 (0) 1133922860.

References 

  1. Bookstein JJ, Chlosta EM, Foley D, Walter JF. Transcatheter hemostasis of gastrointestinal bleeding using modified autogenous clot. Radiology. 1974 Nov;113(2):277–285
  2. Kraybill WG, Harrison M, Sasaki T, Fletcher WS. Regional intra-arterial infusion of adriamycin in the treatment of cancer. Surg Gynecol Obstetrics. 1977 Mar;144(3):335–338
  3. Nicholson AA, Ettles DF, Arnold A, Greenstone M, Dyet JF. Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. J Vasc Interv Radiol. 1997 Sep–Oct;8(5):781–788Clinical Radiology. 48(6):381–5, 1993 Dec
  4. Nicholson AA, Royston CM. Palliation of inoperable biliary obstruction with self-expanding metal endoprostheses: a review of 77 patients. Clin Radiol. 1993 Apr;47(4):245–250
  5. Nicholson AA, Royston CM, Wedgewood K, Milkins R, Taylor AD. Palliation of malignant oesophageal perforation and proximal oesophageal malignant dysphagia with covered metal stents. Clin Radiol. 1995;50(1):11–14
  6. Hess T, Kramann B, Schmidt E, Rupp S. Use of preoperative vascular embolisation in spinal metastasis resection. Arch Orthopaedic Trauma Surg. 1997;116(5):279–282
  7. Lencioni R, Cioni D, Crocetti L, Franchini C, Della Pina C, Lera J, et al. Importantly a randomised controlled trial. Radiology. 2005;234:961;Chen et al Ann Surg (2006) 243:321
  8. de Liquori Carino N, Van Leeuwen B, Ghaneh P, et al. Crit Rev.Oncol Haematol. 2008;67:273
  9. Gillam A, Lees W. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol. 2009;19:1206
  10. Office for National Statistics . Registrations of cancer diagnosed in 2003. England: ONS; 2006;
  11. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999 Jan-Feb;49(1):8–311
  12. Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P. Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol. 2000 Mar;163(3):730–736
  13. McDougal WS, Gervais DA, McGovern FJ, Mueller PR. Long-term followup of patients with renal cell carcinoma treated with radio frequency ablation with curative intent. J Urol. 2005;174(1):61–63
  14. Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma: part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR. 2005;185(1):64–71
  15. Gervais DA, Arellano RS, McGovern FJ, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma: part 2, lessons learned with ablation of 100 tumors. AJR. 2005;185(1):72–80
  16. Levinson AW, Su LM, Agarwal D, Sroka M, Jarrett TW, Kavoussi LR, et al. Long-term oncological and overall outcomes of percutaneous radio frequency ablation in high risk surgical patients with a solitary small renal mass. J Urol. 2008 Aug;180(2):499–504discussion 504. Epub 2008 Jun 11
  17. Permpongkosol S, Link RE, Kavoussi LR, Solomon SB. Percutaneous computerized tomography guided cryoablation for localized renal cell carcinoma: factors influencing success. J Urol. 2006;176(5):1963–1968discussion 1968
  18. Hinshaw JL, Shadid AM, Nakada SY, Hedican SP, Winter TC, Lee FT. Comparison of percutaneous and laparoscopic cryoablation for the treatment of solid renal masses. AJR Am J Roentgenol. 2008;191(4):1159–1168
  19. Trembley BS, Ryan TP, Strohbehn JW. Interstitial hyperthermia: physics, biology and clinical aspects. In:  Urano M,  Douple E editor. Physics of microwave hyperthermia in hyperthermia and oncology. vol. 3:Utrecht, the Netherlands: Verlag Springer; 1992;p. 11–98
  20. Altunrende F, Autorino R, Hillyer S, Yang B, Laydner H, White MA. Image guided percutaneous probe ablation for renal tumors in 65 solitary kidneys: functional and oncological outcomes. Journal of Urology. 2011;186:35–41
  21. Tracy CR, Raman JD, Donnally C, Trimmer CK, Cadeddu JA. Durable oncologic outcomes after radiofrequency ablation: experience from treating 243 small renal masses over 7.5 years. Cancer. 2010;116(13):3135–3142
  22. Zagoria RJ, Pettus JA, Rogers M, Werle DM, Childs D, Leyendecker JR. Long-term outcomes after percutaneous radiofrequency ablation for renal cell carcinoma. Urology. 2011;77(6):1393–1397
  23. Farrell MA, Charboneau JW, Callstrom MR, Reading CC, Engen DE, Blute ML. Paranephric water instillation: a technique to prevent bowel injury during percutaneous renal radiofrequency ablation. AJR. 2003;181(5):1315–1317
  24. Wah TM, Koenig P, Irving HC, Gervais DA, Mueller PR. Radiofrequency ablation of a central renal tumor: protection of the collecting system with a retrograde cold dextrose pyeloperfusion technique. J Vasc Interv Radiol. 2005;16(11):1551–1555
  25. Cantwell CP, Wah TM, Gervais DA, Eisner BH, Arellano R, Uppot RN, et al. Protecting the ureter during radiofrequency ablation of renal cell cancer: a pilot study of retrograde pyeloperfusion with cooled dextrose 5% in water. J Vasc Interv Radiol. 2008;19(7):1034–1040
  26. Gervais DA, McGovern FJ, Wood BJ, Goldberg SN, McDougal WS, Mueller PR. Radio-frequency ablation of renal cell carcinoma: early clinical experience. Radiology. 2000;217(3):665–672
  27. Matin SF, Ahrar K, Cadeddu JA, Gervais DA, McGovern FJ, Zagoria RJ, et al. Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol. 2006 Nov;176(5):1973–1977Erratum in: J Urol. 2008 Jun;179(6):2490. Zagoria, Ronald A
  28. Wah TM, Arellano RS, Gervais DA, Saltalamacchia CA, Martino J, Halpern EF, et al. Image-guided percutaneous radiofrequency ablation and incidence of post-radiofrequency ablation syndrome: prospective survey. Radiology. 2005;237(3):1097–1102
  29. Wah TM, Irving HC. Acute tubular necrosis following radiofrequency ablation of a renal cell carcinoma. Cardiovasc Intervent Radiol. 2007 Nov 6;[epud ahead of print]
  30. Wah TM, Irving HC. Infectious complications after percutaneous radiofrequency ablation of renal cell carcinoma in patients with ileal conduit. J Vasc Interv Radiol. 2008;19(9):1382–1385
  31. Poon RT, Ng KK, Lam CM, Ai V, Yuen J, Fan ST, et al. Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. Ann Surg. 2004;239(4):441–449
  32. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Barcelona Liver Cancer Group. arterial embolisation or chemo-embolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–1739
  33. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–1171
  34. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–442
  35. Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224(1):47–54
  36. Martin RC, Joshi J, Robbins K, Tomalty D, Bosnjakovik P, Derner M, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol. 2011;18(1):192–198
  37. Stubbs RS, Wickremesekera SK. Selective internal radiation therapy (SIRT): a new modality for treating patients with colorectal liver metastases. HPB. 2004;6(3):133–139
  38. Sharma RA, Wasan HS, Love SB, Dutton S, Stokes JC, Smith JL. FOXFIRE Trial Management Group. FOXFIRE: a phase III clinical trial of chemo-radio-embolisation as first-line treatment of liver metastases in patients with colorectal cancer. Clin Oncol. 2008;20(3):261–263

PII: S1078-8174(11)00094-0

doi: 10.1016/j.radi.2011.10.001

Radiography
Volume 18, Issue 1 , Pages 15-20 , February 2012

Article Tools

* Image Usage & Resolution